People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Instil Bio, Inc. | — | Biotechnology | Series D+ | $381.2M | $6.5B | 2020 |
| Innovate Biopharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $154.0M | $791.8M | 2018 |
| Unicycive Therapeutics, Inc. | — | Biotechnology | Series C | $81.7M | $500.3M | 2019 |
| Innovate Biopharmaceuticals Inc. | — | Pharmaceuticals | Series B | $42.7M | $1.1B | 2016 |
| Invea Therapeutics, Inc | — | Biotechnology | Seed | $1.9M | $279K | 2022 |
| Globavir Biosciences Inc. | — | Biotechnology | Pre-Seed | $250K | $8.3M | 2015 |
Sandeep Laumas at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sandeep Laumas on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Ryan | 2 | 17 |
| Christopher Prior | 2 | 3 |
| Shalabh Gupta | 2 | 2 |
| Jay Madan | 2 | 2 |
| Jack Nielsen | 1 | 13 |
| Anthony Maida | 1 | 5 |
| Saira Ramasastry | 1 | 4 |
| Kerrie Brady | 1 | 3 |
| Gaurav Aggarwal | 1 | 3 |
| Edward J. Sitar | 1 | 3 |
| Neil Gibson | 1 | 2 |
| Margo Roberts | 1 | 2 |
| Michael Aiello | 1 | 2 |
| Mariam Morris | 1 | 2 |
| Jonathan Zalevsky | 1 | 2 |
| John Townsend | 1 | 2 |
| Anna Kazanchyan | 1 | 2 |
| Aman Kant | 1 | 1 |
| Demetrios J. Kydonieus | 1 | 1 |
| Devinder Tandon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.